When FDA Trust Is Broken: Lessons from the MedLink Scandal

MedDevice by Design with Mark Drlik and Ariana Wilson
Resources

When FDA Trust Is Broken: Lessons from the MedLink Scandal

Sector: Diagnostics
YouTube video thumbnail

A recent FDA announcement has sent shockwaves through the MedTech community: MedLink, a third-party test house, was found falsifying test data. The consequences? All pending FDA submissions that relied on MedLink’s data have been rejected, delaying or derailing device approvals and costing companies precious time and trust.

In this episode of MedDevice by Design, Ariana Wilson and Mark Drlik examine what happened, what it means for medical device innovators, and how the FDA’s ASCA (Accreditation Scheme for Conformity Assessment) program helps reduce regulatory risk.

The FDA discovered that MedLink had falsified testing data, compromising the integrity of submissions relying on that information. As a result, those submissions are now invalid, and the affected companies must retest their devices and resubmit, costing them months of delay and significant financial loss.

Why ASCA Accreditation Matters

To prevent this kind of disruption, the FDA established the ASCA program in 2020. Labs that receive ASCA accreditation are thoroughly vetted, giving the FDA and submitting companies greater confidence in their test results. Submissions that include ASCA-accredited data benefit from reduced review times—sometimes shaving weeks or even months off approval timelines.

The Tradeoff: Fewer Labs, Higher Costs

As of late 2024, only 47 test houses hold ASCA accreditation, limiting access for some companies. Additionally, ASCA-accredited testing can be 10% to 30% more expensive than non-accredited alternatives. Still, that investment offers peace of mind and regulatory security—especially when the risk of working with an unreliable lab is so high.

Key Takeaway: Prioritize Risk Management


This episode is a reminder of the critical role third-party labs play in the regulatory process. Choosing an ASCA-accredited lab is not just about speed; it’s about reducing risk, protecting your investment, and ensuring trust in your data.

Enjoying MedDevice by Design? Sign up to get new episodes sent to your inbox.

Subscribe to MedTech Insights
Diagram showing medical device at the center connected to clinicians, patients, and regulatory bodies with text 'Who are we designing for?' highlighting stakeholder mapping in MedTech design.

Understanding Medical Device Stakeholders

Every phase of a device’s life cycle involves different people with distinct needs—from clinicians and patients to service technicians and regulatory bodies.

A fluorescent protein assay sample glows under UV light as part of medical device cleaning validation testing.

Fluorescent Protein Assay Testing in Medical Devices

Nick Allan and Nigel Syrotuck explain how a fluorescent protein assay helps engineers measure contamination and cleaning performance in medical devices.

Engineer assembling electronic components during medical device design transfer process.

Bridging the Design-to-Manufacturing Gap in Medical Devices

Your team is ready for design validation. The prototype performs well, test plans are in motion, and everything points to a smooth handoff to manufacturing. Then your partner calls with bad news: they can’t build the device as designed.

Contract Manufacturer Rejection - Engineering team reviews early-stage medical device design and manufacturability during a design transfer meeting at StarFish Medical.

When the CM Says No: What to Do When Your Contract Manufacturer Rejects Your Early-Stage Build

You’ve cleared the toughest engineering hurdles and proven your design works. Then, just as you prepare to scale, your contract manufacturer turns you down.